Pablo Graiver, Antidote

Pablo Graiver, Antidote

Pablo Graiver is CEO of Antidote.

Ozgun Demir, Novartis

Ozgun Demir, Novartis

Ozgun Demir is the director, digital strategy at Novartis.

Wout Brusselaers, Deep 6 AI

Wout Brusselaers, Deep 6 AI

Wout Brusselaers is CEO of Deep 6 AI.

Sundeep Bhan, Prognos

Sundeep Bhan, Prognos

Sundeep Bhan is cofounder and CEO of Prognos.

Ryan Billings, Amag Pharmaceuticals

Ryan Billings, Amag Pharmaceuticals

Ryan Billings is the senior director, digital innovation at Amag Pharmaceuticals.

Heather Bell, Sanofi

Heather Bell, Sanofi

Heather Bell is SVP, global head of digital and analytics of Sanofi.

Jay Appel, Bristol-Myers Squibb

Jay Appel, Bristol-Myers Squibb

Jay Appel is executive director of Bristol-Myers Squibb.

Understanding FDA's Blueprint for Transparency

Understanding FDA's Blueprint for Transparency

The Food and Drug Administration regulates more than a third of the U.S. economy. And its new commissioner, Scott Gottlieb, is trying to shake up how it does so.

McCaskill takes aim at DTC ad tax deduction; measure expected to face stiff resistance

McCaskill takes aim at DTC ad tax deduction; measure expected to face stiff resistance

Pharma companies are likely to put up aggressive resistance to the measure, introduced earlier this month.

Ortho CEO leads massive turnaround

Ortho CEO leads massive turnaround

When Ortho Clinical Diagnostics lived under the roof of Johnson & Johnson, it had the luxury of focusing on its product and service mix — and not a whole lot else.

Teva rebrands in North America amid global restructuring

Teva rebrands in North America amid global restructuring

The pharmaceutical company is undergoing a global restructuring as it relaunches its brand in the U.S. and Canada.

PhRMA takes Let's Talk About Cost campaign to the public

PhRMA takes Let's Talk About Cost campaign to the public

PhRMA wants to clear the air about drug pricing with the consumer-focused extension of the Let's Talk About Cost campaign.

Flexion's pivot proves pain-free

Flexion's pivot proves pain-free

Clayman says the company's next 18 months are all about Zilretta, with further pipeline construction next up.

New tactics change clinical trial awareness game

New tactics change clinical trial awareness game

Recruitment for clinical trials has never been easy. New tools and tactics could change that — assuming the sheer volume of information doesn't overwhelm trial organizers.

Five things for pharma marketers to know: Tuesday, January 16, 2018

Five things for pharma marketers to know: Tuesday, January 16, 2018

Merck's Keytruda combo therapy succeeds in Phase-III lung cancer trial; FDA launches pilot to address trial transparency; Spark's Luxturna overpriced, ICER says

Five things for pharma marketers to know: Thursday, December 21, 2017

Five things for pharma marketers to know: Thursday, December 21, 2017

BI to pay $13.5 million for misleading marketing; ICER: CAR-T therapies more cost-effective than chemotherapy; FDA approves Roche's breast cancer combo therapy

Five things for pharma marketers to know: Tuesday, December 19, 2017

Five things for pharma marketers to know: Tuesday, December 19, 2017

Pharma industry spent $57 million on lobbying in 2016; Humana, private equity firms to buy Kindred for $4 billion; price of old glaucoma drug skyrockets

Five things for pharma marketers to know: Monday, December 18, 2017

Five things for pharma marketers to know: Monday, December 18, 2017

CVS/Aetna deal will affect healthcare benefits; lawmakers pressure DEA to curb painkiller supply; Allergan and Richter's Vraylar sees positive results for bipolar depression

Five things for pharma marketers to know: Friday, December 15, 2017

Five things for pharma marketers to know: Friday, December 15, 2017

FDA approves first topical skin growth treatment; Teva to cut 14,000 jobs; Novartis Oncology CEO resigns

Five things for pharma marketers to know: Tuesday, December 12, 2017

Five things for pharma marketers to know: Tuesday, December 12, 2017

FDA issues prescription drug promotion guidance; FDA approves first follow-on biologic of Lilly's Humalog; drugmakers allegedly hired nurses to promote drugs

Five things for pharma marketers to know: Friday, December 8, 2017

Five things for pharma marketers to know: Friday, December 8, 2017

FDA approves first nebulized LAMA COPD treatment; more than 2,000 cancer immunotherapies in development; FDA issues 3D-printing guidance

Five things for pharma marketers to know: Thursday, December 7, 2017

Five things for pharma marketers to know: Thursday, December 7, 2017

UnitedHealth Group to buy DaVita primary care unit for $4.9 billion; Roche drug combo doubles lung-cancer survival in trial; study: FDA programs expedite drug approval

Five things for pharma marketers to know: Wednesday, December 6, 2017

Five things for pharma marketers to know: Wednesday, December 6, 2017

FDA approves Novo's diabetes drug; Walgreens undergoes rebranding in the wake of CVS-Aetna merger; pharma increasingly transparent about clinical trial data

Five things for pharma marketers to know: Tuesday, December 5, 2017

Five things for pharma marketers to know: Tuesday, December 5, 2017

Botox-like wrinkle-reducer shows positive results in trials; investors double down on fertility; few websites transparent about pricing, study finds

The 2018 pipeline report: Aspiring assets to keep an eye on

The 2018 pipeline report: Aspiring assets to keep an eye on

The most promising products in pharma's pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with a catch.

Five things for pharma marketers to know: Wednesday, November 29, 2017

Five things for pharma marketers to know: Wednesday, November 29, 2017

U.K. to be first to sell OTC Viagra; Regeneron offers startup scientific expertise; docs more likely to get poor marks when they reject patient requests

Five things for pharma marketers to know: Monday, November 27, 2017

Five things for pharma marketers to know: Monday, November 27, 2017

Teva to cut thousands of U.S. jobs; Regeneron drops Eylea combo drug development; insurers, drugstores, and hospitals increasingly teaming up

Five things for pharma marketers to know: Tuesday, November 21, 2017

Five things for pharma marketers to know: Tuesday, November 21, 2017

J&J to hold meeting on maintaining Remicade market share; Acorda ends development of Parkinson's drug; Darzalex notches positive first-line results

Five things for pharma marketers to know: Thursday, November 16, 2017

Five things for pharma marketers to know: Thursday, November 16, 2017

Docs biased against research from poor countries, study finds; Astellas probed over patient-assistance charity support; Acorda reports deaths in Parkinson's trial

Five things for pharma marketers to know: Monday, November 13, 2017

Five things for pharma marketers to know: Monday, November 13, 2017

Dynavax receives FDA approval for hepatitis-B vaccine; Novartis strikes R&D deal with gene-editing startup; White House nominates new HHS head

Five things for pharma marketers to know: Tuesday, November 7, 2017

Five things for pharma marketers to know: Tuesday, November 7, 2017

Senator investigates Alkermes' opioid-marketing tactics; FDA approves Roche cancer drugs; CVS to launch next-day delivery nationwide

Front seat to the comms evolution: Abbott's Melissa Brotz

Front seat to the comms evolution: Abbott's Melissa Brotz

The divisional VP and head of public affairs has seen it all, including the transformation from a traditional comms organization to a more dynamic and content-led group.

Five things for pharma marketers to know: Thursday, October 26, 2017

Five things for pharma marketers to know: Thursday, October 26, 2017

Non-profit challenges Gilead's Sovaldi patent; The Medicines Company to cut hundreds of jobs; Amgen ends R&D for experimental CETP drug

Five things for pharma marketers to know: Monday, October 16, 2017

Five things for pharma marketers to know: Monday, October 16, 2017

FDA briefing document affirms diabetes drug's efficacy; J&J debuts new tools to improve adherence; AZ says cancer drug data was falsified

Infographic | How often are drugmakers sharing clinical-trial data?

Infographic | How often are drugmakers sharing clinical-trial data?

The answer: it depends on what phase the trial is in.

How Pablo Graiver plans to solve the problem of clinical-trial recruitment

How Pablo Graiver plans to solve the problem of clinical-trial recruitment

The CEO and founder of Antidote talks about what inspired him to start the company, which recently received funding from Merck.

Five things for pharma marketers to know: Thursday, September 14, 2017

Five things for pharma marketers to know: Thursday, September 14, 2017

One-third of clinical trials are never publicly registered; ICER revises PCSK9 cost-effectiveness analysis; flu shot linked to miscarriages

Five things for pharma marketers to know: Tuesday, September 12, 2017

Five things for pharma marketers to know: Tuesday, September 12, 2017

Alexion to cut 600 jobs; Sage Therapeutics' experimental seizure drug fails to meet expectations; Apple is interested in medical and health activity

Five things for pharma marketers to know: Friday, September 8, 2017

Five things for pharma marketers to know: Friday, September 8, 2017

Pfizer receives warning letter over EpiPen manufacturing; Opdivo kidney-cancer trial shows improved survival rates; cancer patients who discuss costs with physicians pay less

Can marketing techniques save clinical trials?

Can marketing techniques save clinical trials?

No crucial area in pharma is more desperately in need of a fix — or more stubbornly resistant to change.

Five things for pharma marketers to know: Monday, August 14, 2017

Five things for pharma marketers to know: Monday, August 14, 2017

Merck CEO leaves Trump's manufacturing council over Charlottesville response; researchers struggle to fill clinical trials for IO drugs; Roche shareholders sue over top-line results

Five things for pharma marketers to know: Monday, July 31, 2017

Five things for pharma marketers to know: Monday, July 31, 2017

FDA launches digital health pre-certification pilot; J&J's experimental RA drug raises safety concerns; AstraZeneca gets breakthrough status for Imfinzi

Five things for pharma marketers to know: Friday, July 28, 2017

Five things for pharma marketers to know: Friday, July 28, 2017

Drugmakers inconsistently share clinical trial data; AstraZeneca's share price falls after Mystic results; some pregnancy apps share info with marketers

Otsuka's April Mitchell on leading versus managing

Otsuka's April Mitchell on leading versus managing

When you've figured out the difference, people will walk through fire for you, a mentor once told her.

Five things for pharma marketers to know: Thursday, July 6, 2017

Five things for pharma marketers to know: Thursday, July 6, 2017

The FDA suspends three Keytruda studies; drug and device makers gave $8 billion in payments to providers in 2016; Opdivo beat Yervoy in skin-cancer trial

Five things for pharma marketers to know: Tuesday, June 27, 2017

Five things for pharma marketers to know: Tuesday, June 27, 2017

Merck announces positive trial results for CETP inhibitor; Purdue Pharma defends withholding of OxyContin marketing material; Roche's experimental haemophilia drug significantly cuts bleed rate

Five things for pharma marketers to know: Tuesday, June 20, 2017

Five things for pharma marketers to know: Tuesday, June 20, 2017

Novartis reports positive Phase-III results for Eylea competitor; AZ faces "critical transition point" in MYSTIC trial; physician shortage expected to rise

Five things for pharma marketers to know: Monday, June 19, 2017

Five things for pharma marketers to know: Monday, June 19, 2017

Adamis receives FDA approval for EpiPen rival Symjepi; Clovis reports positive trial results for ovarian cancer drug Rubraca; hedge fund billionaire John Paulson joins Valeant board of directors

Half of clinical-trial sites offer free transportation to patients

Half of clinical-trial sites offer free transportation to patients

Consent forms and reimbursement are the main deterrents of offering the service.

Five things for pharma marketers to know: Monday, June 12, 2017

Five things for pharma marketers to know: Monday, June 12, 2017

Teva gets FDA approval for Truvada generic; the FDA rejects Coherus' Neulasta biosimilar; only 17% of Americans find health industries to be innovative

Five things for pharma marketers to know: Monday, May 22, 2017

Five things for pharma marketers to know: Monday, May 22, 2017

Amgen's osteoporosis drug set back by safety issue; new FDA digital biz to hire 13 engineers; Celgene's MS drug bests Avonex in trial

Five things for pharma marketers to know: Thursday, May 11, 2017

Five things for pharma marketers to know: Thursday, May 11, 2017

FDA approves Merck/Lilly combo for lung cancer; new PhRMA requirements result in expulsion of 22 members; Pfizer to pay Sangamo $7 million for gene therapy programs

Five things for pharma marketers to know: Wednesday, April 26, 2017

Five things for pharma marketers to know: Wednesday, April 26, 2017

GSK warns Advair generic competition may affect business in 2017; Lilly plans to meet FDA about baricitinib; FDA warns companies selling 'illegal' products

Five things for pharma marketers to know: Monday, April 24, 2017

Five things for pharma marketers to know: Monday, April 24, 2017

QuintilesIMS partners with Salesforce; the E.U. to decide on new EMA location by June; drugmakers boost lobbying dollars in Q1

Five things for pharma marketers to know: Monday, April 10, 2017

Five things for pharma marketers to know: Monday, April 10, 2017

Gilead receives approval to market Harvoni, Sovaldi to adolescents; OncoMed ends mid-stage trials for pancreatic cancer drug; researchers use facial recognition software to diagnose

Five things for pharma marketers to know: Monday, April 3, 2017

Five things for pharma marketers to know: Monday, April 3, 2017

Opdivo/Yervoy combination shows improved survival for melanoma patients in trial; global immunotherapy market likely to reach $75 billion by 2022; Mylan expands EpiPen recall

Five things for pharma marketers to know: Wednesday, March 22, 2017

Five things for pharma marketers to know: Wednesday, March 22, 2017

Novartis' heart-failure drug fails in clinical trial; Sanofi, Regeneron file Dupixent patent suit; FDA approves Newron's Xadago for PD

Five things for pharma marketers to know: Monday, March 20, 2017

Five things for pharma marketers to know: Monday, March 20, 2017

Study finds SGLT-2 inhibitors lowered risk of death; former FDA commissioners raise drug importation issues; Bayer, J&J's Xarelto lowered VTE risk in study

Study finds Repatha reduces risk of heart attack, stroke, but cost concerns remain

Study finds Repatha reduces risk of heart attack, stroke, but cost concerns remain

Amgen said it would offer payers a refund for patients who have a heart attack or stroke while taking the PCSK9 inhibitor.

Five things for pharma marketers to know: Monday, March 6, 2017

Five things for pharma marketers to know: Monday, March 6, 2017

Gilead exec blames PBMs for high drug prices; Google uses AI to detect signs of breast cancer; Sanofi and Regeneron drug effective in treating eczema

When It Comes to the FDA, Does It All Come Down to Money?

When It Comes to the FDA, Does It All Come Down to Money?

In our struggle with the bean counters and the stockbrokers, can't we make patient needs a priority, too?

Five things for pharma marketers to know: Thursday, March 2, 2017

Five things for pharma marketers to know: Thursday, March 2, 2017

Ten drugmakers seek to exclude pricing information from proxy ballots; roughly 85% of patient advocacy groups get industry funding; Juno halts lead CAR-T project

Five things for pharma marketers to know: Wednesday, February 15, 2017

Five things for pharma marketers to know: Wednesday, February 15, 2017

Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto

Five things for pharma marketers to know: Tuesday, February 7, 2017

Five things for pharma marketers to know: Tuesday, February 7, 2017

Teva CEO steps down; Mylan to pay $96.5 million to settle pay-for-delay claims; Merck files Keytruda with the FDA for bladder cancer

Five things for pharma marketers to know: Friday, February 3, 2017

Five things for pharma marketers to know: Friday, February 3, 2017

Trial finds that Repatha reduces risk of heart attack and stroke; California measure would ban drug coupons in some cases; Takeda to limit price increases

Continuum and Lyft to offer free rides to clinical-trial patients

Continuum and Lyft to offer free rides to clinical-trial patients

Transportation barriers can limit patient involvement in clinical trials.

Five things for pharma marketers to know: Wednesday, January 25, 2017

Five things for pharma marketers to know: Wednesday, January 25, 2017

Novartis forecasts slower growth in 2017; Actelion reports trial failure for PAH drug; HHS nominee Tom Price denies conflict of interest claims

For statin-intolerant patients, what's next?

For statin-intolerant patients, what's next?

Despite their blockbuster status and distinction as the world's most widely prescribed class of drugs, statins may not be the best option for all patients with elevated low density lipoprotein (LDL) cholesterol levels.

Five things for pharma marketers to know: Wednesday, December 21, 2016

Five things for pharma marketers to know: Wednesday, December 21, 2016

GSK's two-drug combo for HIV has positive Phase-III results; the FDA approves glucose system that doesn't use finger pricking; Rite Aid to sell stores

Five things for pharma marketers to know: Thursday, December 15, 2016

Five things for pharma marketers to know: Thursday, December 15, 2016

Drugmakers promote new type of opioid with unproven results; Heritage execs charged for price-fixing generics; Pershing sells more Valeant shares

Five things for pharma marketers to know: Friday, December 9, 2016

Five things for pharma marketers to know: Friday, December 9, 2016

BMS to pay $19.5 million to settle marketing violations for Abilify; AstraZeneca to cut 700 U.S. jobs; Trump reportedly considering Jim O'Neill to lead FDA

GSK and Propeller Health's smart inhaler aims to improve adherence in clinical trials

GSK and Propeller Health's smart inhaler aims to improve adherence in clinical trials

The drugmaker is using Propeller Health's sensor technology to find new ways to improve adherence in clinical studies.

Five things for pharma marketers to know: Monday, December 5, 2016

Five things for pharma marketers to know: Monday, December 5, 2016

The FDA approves new indication for Jardiance; Novartis' CAR-T therapy eliminates leukemia in 82% of patients in trial; doctors report risks associated with immunotherapy

MM&M's top 5 stories in November 2016

MM&M's top 5 stories in November 2016

How VR, nanotechnology, and 3D printing could improve the value of healthcare; 100 experimental therapies in late-stage clinical trials; Kite Pharma plans "controlled" launch of CAR-T therapy

The 2017 pipeline report: What to know about next year's launches

The 2017 pipeline report: What to know about next year's launches

Here's a look at 100 experimental therapies in late-stage clinical trials.

Five things for pharma marketers to know: Wednesday, November 23, 2016

Five things for pharma marketers to know: Wednesday, November 23, 2016

Lilly's experimental Alzheimer's drug fails in another trial; two more patients die during trial for Juno's CAR-T therapy; NEJM launches platform in China

Five things for pharma marketers to know: Tuesday, November 22, 2016

Five things for pharma marketers to know: Tuesday, November 22, 2016

Intarcia submits diabetes drug-delivery pump for FDA approval; Shire to build rare-disease innovation hub; AstraZeneca to resume durvalumab trials

Five things for pharma marketers to know: Monday, November 21, 2016

Five things for pharma marketers to know: Monday, November 21, 2016

Novartis to delay clinical trials of contact lens for diabetes patients; the ADA calls for hearings on insulin pricing; Vice launches healthcare channel

Five things for pharma marketers to know: Monday, November 14, 2016

Five things for pharma marketers to know: Monday, November 14, 2016

J&J's experimental RA drug has mixed results in clinical trial; Novartis reportedly considers buying generics maker; Donald Trump names healthcare transition team leader

Five things for pharma marketers to know: Tuesday, November 8, 2016

Five things for pharma marketers to know: Tuesday, November 8, 2016

FDA solicits public comment to study online character space limit; Biogen's Spinraza shows positive results in SMA study; Valeant cuts earnings forecast

Interview | Jeanne Martel, ClinicalMind

Interview | Jeanne Martel, ClinicalMind

Jeanne Martel, president and partner at ClinicalMind, highlights her company's vision and role in communication and technology with MM&M's Jaimy Lee. This video was sponsored by ClinicalMind.

Five things for pharma marketers to know: Tuesday, September 27, 2016

Five things for pharma marketers to know: Tuesday, September 27, 2016

Amgen's Kyprolis fails to best Velcade in trial; diabetes drugs have lower than average FDA approval rate; Bayer's derm business draws interest

Five things for pharma marketers to know: Friday, September 23, 2016

Five things for pharma marketers to know: Friday, September 23, 2016

Anthem and Cigna accuse each other of violating merger terms; Alzheimer's experimental drug fails late-stage study; study calls for new approach to eradicate global epidemics

The Michael J. Fox Foundation uses Facebook to recruit Ashkenazi Jews for Parkinson's study

The Michael J. Fox Foundation uses Facebook to recruit Ashkenazi Jews for Parkinson's study

The organization said it used Facebook to identify participants for a study designed to identify biomarkers associated with Parkinson's disease.

Five things for pharma marketers to know: Tuesday, September 13, 2016

Five things for pharma marketers to know: Tuesday, September 13, 2016

Drugmakers routinely pay ghostwriters to write industry-funded research articles; Horizon to buy Raptor for $800 million; WellDoc partners with J&J

Bolstered by new data, Radius Health focuses on unmet needs in the osteoporosis market

Bolstered by new data, Radius Health focuses on unmet needs in the osteoporosis market

Only one new osteoporosis drug has been approved over the last six years.

Five things for pharma marketers to know: Tuesday, August 16, 2016

Five things for pharma marketers to know: Tuesday, August 16, 2016

OncoGenex's prostate cancer drug fails in clinical trial; Aetna to exit exchanges in 11 states; pregnant women taking acetaminophen have higher risks for their children

Five things for pharma marketers to know: Thursday, August 11, 2016

Five things for pharma marketers to know: Thursday, August 11, 2016

Valeant is under federal investigation; Lilly's breast-cancer drug fails to meet efficacy criteria; new policy opens up medical research of marijuana

Five things for pharma marketers to know: Tuesday, August 9, 2016

Five things for pharma marketers to know: Tuesday, August 9, 2016

Novo Nordisk attributes slow growth to biosimilars, pricing; Dentsu acquires majority stake in Merkle; AZ lung cancer drug fails late-stage trial

Event company acquires AstraZeneca's medical meetings app

Event company acquires AstraZeneca's medical meetings app

The event technology platform plans to integrate a conference note-taking app developed by AstraZeneca and DigitasLBi.

Five things for pharma marketers to know: Thursday, August 4, 2016

Five things for pharma marketers to know: Thursday, August 4, 2016

Researchers test Zika vaccine; Aetna contacts doctors who prescribe high rates of opioids; half of pediatric trials are never published or completed

Five things for pharma marketers to know: Tuesday, July 19, 2016

Five things for pharma marketers to know: Tuesday, July 19, 2016

The FDA declines to approve Novartis biosimilar; GSK partners with Apple's ResearchKit; drugmakers partner with Lyft for clinical trial participants

Five things for pharma marketers to know: Thursday, July 14, 2016

Five things for pharma marketers to know: Thursday, July 14, 2016

The FDA expands use for Pfizer's Prevnar 13 vaccine; an FDA panel votes in support of Novartis biosimilar; U.S. healthcare spending rises 5.5% in 2015

Five things for pharma marketers to know: Monday, June 13, 2016

Five things for pharma marketers to know: Monday, June 13, 2016

A new Sanofi combination diabetes drug meets clinical trial targets; IBM partners with the American Diabetes Association; Dr. Reddy's to buy eight Teva drugs

Pharma companies turn to wearables to improve R&D

Pharma companies turn to wearables to improve R&D

Drugmakers and tech companies are developing wearables and using popular fitness trackers like the Fitbit in clinical trials to gain insights about Parkinson's Disease.

Five things for pharma marketers to know: Thursday, May 19, 2016

Five things for pharma marketers to know: Thursday, May 19, 2016

Novartis plans new trials for Entresto; U.S. spending on mental health topped $201 billion in 2013; the FDA approves Roche's immunotherapy drug

Five things for pharma marketers to know: Tuesday, April 19, 2016

Five things for pharma marketers to know: Tuesday, April 19, 2016

Novartis CEO under pressure to restore investor confidence; Orexigen terminates obesity drug; startup invests in shaky cholesterol-drug class

Infographic: Better promotion of clinical trials

Infographic: Better promotion of clinical trials

Companies spend $2 billion per year recruiting patients for clinical trials. A survey of 702 adults, conducted from December 2015 to January 2016, points to a need for more awareness.

Levy joins PatientsLikeMe, bringing the analyst closer to the patient in latest career move

Levy joins PatientsLikeMe, bringing the analyst closer to the patient in latest career move

Monique Levy, who's spent more than a decade helping drugmakers understand technology shifts, has joined PatientsLikeMe, the online discussion platform for people with chronic illness.

Precision for Medicine acquires ACT Oncology

Precision for Medicine acquires ACT Oncology

The scientific services company expands its portfolio to include expertise in oncology clinical studies.